Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28887307 | 1.00 | BLM (0.59) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL22078474 | 0.92 | BLM (0.52) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL24311101 | 0.90 | BLM (0.55) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL20994108 | 0.86 | BLM (0.55) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL28010734 | 0.86 | LMNA (0.61) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL2828866 | 0.86 | BLM (0.59) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL1116070 | 0.84 | BLM (0.63) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL31276194 | 0.84 | BLM (0.57) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL8813670 | 0.84 | BLM (0.57) | BLMLMNAPTPN1MEN1CYP3A4 | |
| SCHEMBL277518 | 0.84 | BLM (0.63) | BLMLMNAPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-10 | — | — | US | disclosed |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-10 | — | — | US | disclosed |
| US-20190240339-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2019-08-08 | — | — | US | disclosed |
| US-20180071397-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20180071397-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-15 | — | — | US | disclosed |
| US-9878042-B2 | Lipid formulations for delivery of therapeutic agents to solid tumors | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2018-01-30 | — | — | US | disclosed |
| US-9878042-B2 | Lipid formulations for delivery of therapeutic agents to solid tumors | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2018-01-30 | — | — | US | disclosed |
| US-8236943-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-08-07 | — | — | US | disclosed |
| US-20110201667-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | US | disclosed |
| US-20110201667-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-08-18 | — | — | US | disclosed |
| US-20110195127-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110195127-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-08-11 | — | — | US | disclosed |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| WO-2011011447-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011000106-A1 | IMPROVED CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000108-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | BLM 2844/4885LMNA 883/4885PTPN1 1864/4885 |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | BLM 2897/4885LMNA 758/4885PTPN1 2028/4885 |
| US-20190240339-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | BLM 2844/4885LMNA 883/4885PTPN1 1864/4885 |
| US-20110201667-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | BST2, AGO2, SCARB1 | BLM 3614/4885LMNA 572/4885PTPN1 2901/4885 |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | BLM 3014/4885LMNA 793/4885PTPN1 1747/4885 |
| US-20110195127-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | BLM 1843/4885LMNA 128/4885PTPN1 1664/4885 |
| US-20180071397-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | BLM 2844/4885LMNA 883/4885PTPN1 1864/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | BLM 3014/4885LMNA 793/4885PTPN1 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.